Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human GSK5471713 study in metastatic castration-resistant prostate cancer
NL-OMON61393Phase 2Recruiting
- Sponsor
- GSK
- Start
- Oct 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GSK5471713 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by GSK. Primary endpoints: Dose-limiting toxicities, Adverse events and 1 more. Started Oct 2026; status: recruiting.
02
Drugs
GSK5471713
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON61393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61393.